E
CERE

Ergoteles’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ergoteles’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,405
Closed -$425K – 1654
2023
Q1 		$425K Buy
+17,405
New +$511K 0.02% 792

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ergoteles's CERE Position: Q2 2023 in Review

Ergoteles sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2023, closing a stake of 17,405 shares — an estimated $425K sold.

Ergoteles first reported a position in CERE in Q1 2023 and held it in 1 quarter. The position peaked at $425K in Q1 2023. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

  • Ergoteles reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 17,405 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2023, an estimated $425K.
  • Ergoteles first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Ergoteles's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $425K in Q1 2023.
  • 125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.